Search | Clinical Trials Finder

Conditions: Urinary Incontinence
Interventions: DR-3001a, DR-3001b, Placebo; Drug · Other
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 46
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 42 more

Conditions: Overactive Bladder
Interventions: Botox; Drug
Lead sponsor: Urological Sciences Research Foundation; Other
Eligibility: 40 Years to 90 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Culver City, California

Conditions: Urinary Bladder, Overactive
Interventions: Mirabegron, Tolterodine, Placebo to Mirabegron, Placebo to Tolterodine; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 2,792 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 106
States / cities: Homewood, Alabama • Huntsville, Alabama • Mobile, Alabama + 96 more

Conditions: Urinary Incontinence
Interventions: Tolterodine ER 4 mg QD, Tamsulosin 0.4 mg QD; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 40 Years and older · Male only
Enrollment: 830 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 95
States / cities: Birmingham, Alabama • Homewood, Alabama • Tucson, Arizona + 92 more

Conditions: Urinary Incontinence, Stress
Interventions: SS-RBX; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 402 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 89
States / cities: Anchorage, Alaska • Sun City, Arizona • Tucson, Arizona + 78 more

Conditions: Overactive Bladder
Interventions: Fesoterodine, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years and older
Enrollment: 566 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 125
States / cities: Birmingham, Alabama • Montgomery, Alabama • Green Valley, Arizona + 106 more

Conditions: Urinary Incontinence
Interventions: Botox, Placebo; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 21 Years to 90 Years · Female only
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2011
U.S. locations: 3
States / cities: Sacramento, California • Boston, Massachusetts • Durham, North Carolina

Conditions: Overactive Bladder
Interventions: Solifenacin, Placebo; Drug · Other
Lead sponsor: Cleveland Clinic Florida; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Weston, Florida

Conditions: Overactive Bladder
Interventions: vibegron, Vibegron placebo, Tolterodine Tartrate ER, Tolterodine placebo; Drug
Lead sponsor: Urovant Sciences GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 1,530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 191
States / cities: Birmingham, Alabama • Gulf Shores, Alabama • Huntsville, Alabama + 155 more

Conditions: Overactive Bladder (OAB)
Interventions: Mirabegron, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 888 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 103
States / cities: Huntsville, Alabama • Mobile, Alabama • Anchorage, Alaska + 88 more

Conditions: Overactive Bladder
Interventions: Oxybutynin topical gel, Placebo topical gel; Drug · Other
Lead sponsor: Watson Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 789 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 63
States / cities: Birmingham, Alabama • Homewood, Alabama • Mobile, Alabama + 60 more

Conditions: Urinary Incontinence, Overactive Bladder
Interventions: Botulinum toxin type A, Placebo; Biological · Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 32
States / cities: Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 27 more

Conditions: Overactive Bladder
Interventions: SSR240600C, Placebo, Tolterodine; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 22
States / cities: Phoenix, Arizona • Tuscon, Arizona • San Diego, California + 19 more

Conditions: Urinary Incontinence
Interventions: tolterodine; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Urinary Incontinence
Interventions: Tolterodine ER 4mg QD; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 58
States / cities: Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 46 more

Conditions: Overactive Bladder, Urinary Urge Incontinence, Urinary Bladder, Neurogenic, Painful Bladder Syndrome
Interventions: Onabotulinumtoxin A (BoNT), belladonna, Morphine, Placebo, Active B&O suppository of belladonna; Drug
Lead sponsor: Edgar LeClaire, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Wichita, Kansas

Conditions: Overactive Bladder, Overactive Bladder (OAB), Urge Urinary Incontinence, Mixed Urinary Incontinence (Urge-Predominant), Mixed Urinary Incontinence, Idiopathic Overactive Bladder With Urinary Incontinence, Idiopathic Overactive Bladder
Interventions: Detrusor nerve radiofrequency ablation, Simulated (sham) detrusor nerve radiofrequency ablation; Device
Lead sponsor: InMode MD Ltd.; Industry
Eligibility: 22 Years to 80 Years · Female only
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 9
States / cities: Palo Alto, California • Washington D.C., District of Columbia • Boise, Idaho + 6 more

Conditions: Urinary Urge, Urge Incontinence, Overactive Bladder
Interventions: solifenacin succinate, placebo; Drug
Lead sponsor: Stamford Hospital; Other
Eligibility: 20 Years to 45 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Stamford, Connecticut

Conditions: Overactive Bladder
Interventions: Solabegron modified release tablets, low dose, Solabegron modified release tablets, high dose, Matching Placebo; Drug
Lead sponsor: Velicept Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 1,413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 77
States / cities: Birmingham, Alabama • Guntersville, Alabama • Saraland, Alabama + 61 more

Conditions: Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases
Interventions: mirabegron 25 mg, mirabegron 50 mg, solifenacin 5 mg, solifenacin 10 mg, mirabegron 25 mg matching placebo, mirabegron 50 mg matching placebo, solifenacin 5 mg matching placebo, solifenacin 10 mg matching placebo; Drug
Lead sponsor: Astellas Pharma Europe Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 2,174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 36
States / cities: Tucson, Arizona • Buena Park, California • Los Angeles, California + 31 more

Conditions: Urinary Bladder, Overactive, Urinary Incontinence
Interventions: onabotulinumtoxinA, Placebo (saline); Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 31
States / cities: Laguna Hills, California • Los Angeles, California • Orange, California + 27 more

Conditions: Overactive Bladder (OAB)
Interventions: Detrol LA; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 40 Years and older · Male only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 11
States / cities: Anaheim, California • La Mesa, California • Aurora, Colorado + 8 more

Conditions: Overactive Bladder
Interventions: onaBoNT-A, Oxybutynin ER; Drug
Lead sponsor: Christopher Patrick Smith; Other
Eligibility: 18 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Interstitial Cystitis, Chronic Interstitial Cystitis, Bladder Pain Syndrome
Interventions: Desert Harvest Aloe Vera Capsules, Placebo Capsules; Drug · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Search by objective public record fields.

Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder

This is a Prospective, Randomized, Double-Blind Study Comparing Intravesical Injection of Botox® to Placebo.

Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction

An 8 Week Study Looking At The Efficacy, Toleration And Safety Of SS-RBX For Stress Urinary Incontinence.

A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder

A Multi-Center Trial of Botox for Severe Urge Urinary Incontinence

Over Active Bladder Patients Having Sling Surgery

A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)

Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)

A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1

MILADY: A Randomized, Placebo-controlled Safety and Efficacy Trial of SSR240600C in Treatment of Overactive Bladder or Urge Urinary Incontinence.

A Comparison of Tolterodine and Placebo Treatments on Nocturnal Frequency and Sleep Quality in Women After Menopause.

Effect of Detrol LA on Overactive Bladder Symptoms, Sexual Quality of Life and Sexual Function in Women

Reduction of Bladder Injection Pain With Belladonna Opiate Suppository

Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women

Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder

A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)

Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence

Detrol LA In Men With Overactive Bladder.

OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER

Safety and Efficacy of Aloe Vera in the Management of the Symptoms of Interstitial Cystitis